Supplementary Material: Switching From Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 52 Week Safety and Efficacy Results From an Open-Label Extension of the Phase 3 Heads Up Study

Name: Supplementary Material: Switching From Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 52 Week Safety and Efficacy Results From an Open-Label Extension of the Phase 3 Heads Up Study
Creator: Vimal H Prajapati
Published: 2026-06-02T15:14:44.956Z
Keywords: Dermatology, Dermatitis

Prajapati, Vimal H; Laquer, Vivian; Song, Eingun James; Barbarot, Sébastien; Spelman, Lynda; Huilaja, Laura; Kwiek, Bartlomiej; Goel, Shilpa Aditya; Grada, Ayman; Wu, Tianshuang; Levy, Gweneth; Hu, Xiaofei; Calimlim, Brian; Moreira, Alvaro; Eyerich, Kilian

doi:10.17632/6r7rhd49z8.3

Supplementary Material: Switching From Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 52 Week Safety and Efficacy Results From an Open-Label Extension of the Phase 3 Heads Up Study

Published: 2 June 2026| Version 3 | DOI: 10.17632/6r7rhd49z8.3

Contributors:

Vimal H Prajapati, Vivian Laquer, Eingun James Song, Sébastien Barbarot, Lynda Spelman, Laura Huilaja, Bartlomiej Kwiek, Shilpa Aditya Goel, Ayman Grada, Tianshuang Wu, Gweneth Levy, Xiaofei Hu, Brian Calimlim, Alvaro Moreira, Kilian Eyerich

Description

Switching From Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 52-Week Efficacy and Safety Results From an Open-Label Extension of the Phase 3 Heads Up Study

Files

Funders

AbbVie (United States)
Illinois, United States

Supplementary Material: Switching From Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 52 Week Safety and Efficacy Results From an Open-Label Extension of the Phase 3 Heads Up Study

Description

Files

Categories

Funders

Licence